What question did this study set out to answer?

To evaluate the reactogenicity and immunogenicity associated with a delayed second dose or a third booster dose of the ChAdOx1 nCoV-19 vaccine.

September 1, 2021The LancetOpen Access

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

View Full Paper

Ask AI

Bookmark

To evaluate the reactogenicity and immunogenicity associated with a delayed second dose or a third booster dose of the ChAdOx1 nCoV-19 vaccine.
Substudy nested within two randomized controlled trials (COV001 and COV002) conducted across multiple centers in the United Kingdom.
Assessed adverse reaction profiles and humoral immune responses following extended intervals between the primary series doses or after an additional third dose.
Administration of a delayed second dose or a third booster dose elicited robust increases in antibody titers without escalating reactogenicity.
Local and systemic adverse events following late second or third doses were generally mild to moderate and resolved quickly, presenting no unexpected safety concerns.

Implication

Randomized trial substudy reveals reactogenicity and immunogenicity after delayed second or third ChAdOx1 nCoV-19 doses in UK adults, indicating durable immune boosting.

Abstract

UK Research and Innovation, Engineering and Physical Sciences Research Council, National Institute for Health Research, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research Oxford Biomedical Research Centre, Chinese Academy of Medical Sciences Innovation Fund for Medical Science, Thames Valley and South Midlands NIHR Clinical Research Network, AstraZeneca, and Wellcome.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Flaxman et al. (2021) studied this question.

synapsesocial.com/papers/69dd4b807d97b7e86940cac0 https://doi.org/10.1016/s0140-6736(21)01699-8

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial substudy reveals reactogenicity and immunogenicity after delayed second or third ChAdOx1 nCoV-19 doses in UK adults, indicating durable immune boosting.

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Key Points

Implication

Abstract

Discussion

Cite This Study

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading